Agilent Technologies, Inc. announced it is selling Resolution Bioscience Inc. to Exact Sciences Corp. Financial terms of the agreement were not disclosed and are not material to either party. According to data captured in the LevinPro HC database, this transaction represents the 108th Biotechnology acquisition of 2023.
Resolution Bioscience is dedicated to developing a highly sensitive, non-invasive liquid biopsy platform that improves cancer diagnostics and monitoring for patients around the world. The company has developed and patented core technology for circulating cell-free DNA NGS analysis.
Exact Sciences is a molecular diagnostics company which focuses on the early detection and prevention of colorectal cancer. Nearly 300,000 health care providers and more than 200 large U.S. health systems rely on Exact Sciences’ Cologuard® and Oncotype DX® tests in primary care, women’s health, oncology and other specialties.
Founded in 1999, Agilent provides bio-analytical solutions and services to the life sciences, diagnostics, and genomics, chemical analysis, communications and electronics industries worldwide. It originally purchased Resolution Bioscience in March 2021 for $695 million.
According to the press release, Agilent had previously planned to close Resolution Bioscience, citing lower-than-expected sales of its next-generation sequencing-based companion diagnostics and with little profitability.
